Ignite Creation Date:
2024-05-06 @ 1:06 AM
Last Modification Date:
2024-10-26 @ 10:59 AM
Study NCT ID:
NCT01736813
Status:
COMPLETED
Last Update Posted:
2017-03-22
First Post:
2012-10-24
Brief Title:
CCR5-blockade in Metastatic Colorectal Cancer
Sponsor:
National Center for Tumor Diseases Heidelberg
Organization:
National Center for Tumor Diseases Heidelberg
Study Overview
Official Title:
Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc Phase I Maracon Trial
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MARACON
Brief Summary:
The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal cancer Inhibition of this molecule leads to a reduction in growth signals for tumor cells and subsequent slowed or halted tumor growth The agent for the inhibition of CCR5 has already received FDA approval for treatment of HIV and has shown little side effects and toxicities even on long term treatment Therefore CCR5-inhibition has the potential of providing non-toxic tumor growth inhibition
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-000861-18 | EUDRACT_NUMBER | None | None |